Payment overview · 2025
General Payments
$41.37
2 reported records · 2 companies
Healthcare provider profile · identity verified
Christopher James Edmands, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · PARKERSBURG, WV · NPI 1912955758
Verified facts
What the public records show
CMS Open Payments records show Christopher James Edmands, D.O. received $41.37 in general payments during 2025 across 2 reported records.
Exact Sciences Corporation accounted for 61.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.55 | 61.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.82 | 38.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $41.37 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 56 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
56 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 286 | 70 |
| Lisinopril | Lisinopril | 278 | 73 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 260 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 205 | 59 |
| Gabapentin | Gabapentin | 202 | 40 |
| Losartan Potassium | Losartan Potassium | 196 | 46 |
| Metformin Hcl | Metformin Hcl | 188 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 184 | 56 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 179 | 28 |
| Alprazolam | Alprazolam | 148 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 144 | 45 |
| Meloxicam | Meloxicam | 143 | 46 |
| Allopurinol | Allopurinol | 141 | 35 |
| Furosemide | Furosemide | 133 | 47 |
| Omeprazole | Omeprazole | 133 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 110 | 26 |
| Tramadol Hcl | Tramadol Hcl | 107 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 105 | 32 |
| Temazepam | Temazepam | 100 | 12 |
| Montelukast Sodium | Montelukast Sodium | 90 | 23 |
| Pregabalin | Pregabalin | 89 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 87 | 25 |
| Simvastatin | Simvastatin | 87 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 83 | 30 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 33 |
| Finasteride | Finasteride | 77 | 21 |
| Methylprednisolone | Methylprednisolone | 76 | 48 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 11 |
| Trazodone Hcl | Trazodone Hcl | 76 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 31 |
| Eliquis | Apixaban | 73 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 21 |
| Pioglitazone Hcl | Pioglitazone Hcl | 70 | 13 |
| Potassium Chloride | Potassium Chloride | 68 | 21 |
| Celecoxib | Celecoxib | 67 | 18 |
| Cefdinir | Cefdinir | 61 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 21 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 58 | 11 |
| Synthroid | Levothyroxine Sodium | 56 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 55 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 13 |
| Sucralfate | Sucralfate | 52 | 26 |
| Carvedilol | Carvedilol | 51 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 11 |
| Buspirone Hcl | Buspirone Hcl | 42 | 11 |
| Metformin Hcl Er | Metformin Hcl | 41 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 40 | 14 |
| Ozempic | Semaglutide | 40 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 40 | 11 |
| Warfarin Sodium | Warfarin Sodium | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 38 | 15 |
| Bupropion Xl | Bupropion Hcl | 38 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 38 | 21 |
| Repatha Sureclick | Evolocumab | 38 | suppressed |
| Azithromycin | Azithromycin | 37 | 32 |
| Colestipol Hcl | Colestipol Hcl | 36 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 35 | 22 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 22 |
| Spironolactone | Spironolactone | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Entresto | Sacubitril/Valsartan | 28 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 19 |
| Famotidine | Famotidine | 24 | suppressed |
| Lorazepam | Lorazepam | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 18 |
| Cephalexin | Cephalexin | 21 | 16 |
| Prednisone | Prednisone | 21 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | suppressed |
| Metronidazole | Metronidazole | 20 | 16 |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 16 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Nystatin | Nystatin | 17 | 11 |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | 14 |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Creon | Lipase/Protease/Amylase | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $41.37 · 2 records | Exact Sciences Corporation | Cologuard Collection Kit, SYNTHROID, UBRELVY | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Synthroid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error